Evidence map›Paper›PMID 41881502›Full record

Trial reportJournal for immunotherapy of cancer2026

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Chennan Li, Ravi A Madan, Min-Jung Lee, Sunmin Lee, Nahoko Sato, Shraddha Rastogi, Roshan Shrestha, Jeanny B Aragon-Ching, Meghali Goswami, Renee N Donahue and 18 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02484404 (Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02484404 phase1 / phase2active not recruitingnot on this map

Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2015 to 2027Enrolled268ConditionsColorectal Neoplasms, Breast NeoplasmsArmsOlaparib, Cediranib, Durvalumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Chennan LiGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Ravi A MadanGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0001-5106-8636
Min-Jung LeeDevelopmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA.
Sunmin LeeDevelopmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA.
Nahoko SatoDevelopmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA.
Shraddha RastogiDevelopmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA.
Roshan ShresthaDevelopmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA.
Jeanny B Aragon-ChingInova Schar Cancer Institute, Fairfax, Virginia, USA.
Meghali GoswamiCenter for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA.
Renee N DonahueCenter for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-6828-3073
Lisa M CordesGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0003-3833-4084
Anna BajGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Clara C Y SeoGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Nicholas T TerriginoGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
John R BrightGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
S Thomas HenniganGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Isaiah M KingGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Shana Y TrostelGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
John M FenimoreGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Yi LiuGenetics Branch, National Cancer Institute, Bethesda, Maryland, USA.
Kathleen A CalzoneGenetics Branch, National Cancer Institute, Bethesda, Maryland, USA.
Jeffrey SchlomCenter for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0001-7932-4072
James L GulleyCenter for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-6569-2912
William L DahutGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
William D FiggGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Adam G SowalskyGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0003-2760-1853
Jung-Min Lee *Women's Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
Fatima Karzai *Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA fatima.karzai@nih.gov.ORCID http://orcid.org/0000-0002-3244-1332

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPoly(ADP-ribose) polymerase (PARP) inhibition (PARPi) is a precision medicine strategy in advanced prostate cancer, with the greatest benefit seen in a subset of patients with homologous recombination repair (HRR) gene alterations. Combination approaches may expand activity beyond HRR-altered disease. We conducted a phase 2 study of the PARP inhibitor olaparib in combination with the anti-PD-L1 antibody durvalumab in an HRR-unselected population of men with metastatic castration-resistant prostate cancer (mCRPC).

methodsThis is a single-arm, open-label phase 2 trial of olaparib plus durvalumab in men with mCRPC previously treated with abiraterone and/or enzalutamide. Pretreatment biopsies of metastatic lesions were attempted for tumor sequencing. Peripheral blood was collected longitudinally for immune profiling of cell subsets and soluble factors, circulating tumor DNA (ctDNA) analyses, and peripheral blood mononuclear cell (PBMC) gene expression profiling.

results61 patients were enrolled; 60 were evaluable. Median age was 65 years (45-88). Median radiographic progression-free survival (rPFS) was 5.0 months (95% CI 4.6 to 7.6) and median overall survival (OS) was 19.1 months (95% CI 15.0 to 29.3 months). 10 patients achieved partial responses, and 17 (28%) had ≥50% prostate-specific antigen declines. Patients with

conclusionsOlaparib plus durvalumab demonstrated modest activity in HRR-unselected mCRPC, with clinical benefit enriched in TRIAL REGISTRATION NUMBER: NCT02484404.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsPhthalazinesPiperazinesProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overHumansMaleMiddle AgedNeoplasm MetastasisAntibodies, MonoclonaldurvalumabolaparibPhthalazinesPiperazinesGENETICSImmunotherapyProstate CancerT regulatory cell - Treg

Identifiers

PMID41881502
PMCPMC13034327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.